Aegis Affirms Progenics Pharma (PGNX) at 'Buy'; Solid Relistor Results Fuel Q3 Revenue Gains (VRX)
Tweet Send to a Friend
Aegis Capital affirms Progenics Pharma (Nasdaq: PGNX) at Buy with a price target of $11 following Q3 results issued on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
